Clovis Oncology Stock Z Score
CLVSDelisted Stock | USD 0.09 0.02 24.00% |
Clovis |
Clovis Oncology Company Z Score Analysis
Clovis Oncology's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Current Clovis Oncology Z Score | -5.6 |
Most of Clovis Oncology's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clovis Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
CompetitionIn accordance with the company's disclosures, Clovis Oncology has a Z Score of -5.6. This is 182.96% lower than that of the Biotechnology sector and 267.66% lower than that of the Health Care industry. The z score for all United States stocks is 164.22% higher than that of the company.
Did you try this?
Run Pattern Recognition Now
Pattern RecognitionUse different Pattern Recognition models to time the market across multiple global exchanges |
All Next | Launch Module |
Clovis Fundamentals
Return On Asset | -0.3 | |||
Profit Margin | (1.89) % | |||
Operating Margin | (1.55) % | |||
Current Valuation | 651.32 M | |||
Shares Outstanding | 144.96 M | |||
Shares Owned By Insiders | 1.43 % | |||
Shares Owned By Institutions | 25.89 % | |||
Number Of Shares Shorted | 28.49 M | |||
Price To Earning | (8.65) X | |||
Price To Sales | 0.11 X | |||
Revenue | 148.76 M | |||
Gross Profit | 115.3 M | |||
EBITDA | (224.76 M) | |||
Net Income | (264.52 M) | |||
Cash And Equivalents | 94.58 M | |||
Cash Per Share | 0.65 X | |||
Total Debt | 436.77 M | |||
Debt To Equity | 810.00 % | |||
Current Ratio | 1.17 X | |||
Book Value Per Share | (2.89) X | |||
Cash Flow From Operations | (196.06 M) | |||
Short Ratio | 4.63 X | |||
Earnings Per Share | (2.08) X | |||
Price To Earnings To Growth | 0.13 X | |||
Target Price | 2.0 | |||
Number Of Employees | 413 | |||
Beta | 0.22 | |||
Market Capitalization | 11.77 M | |||
Total Asset | 472.83 M | |||
Retained Earnings | (2.3 B) | |||
Working Capital | 464.12 M | |||
Current Asset | 539.7 M | |||
Current Liabilities | 75.58 M | |||
Z Score | -5.6 | |||
Net Asset | 472.83 M |
About Clovis Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clovis Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clovis Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clovis Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Clovis Stock
If you are still planning to invest in Clovis Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Clovis Oncology's history and understand the potential risks before investing.
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |